Research ArticleFeatured Articles

The Role of Chemotherapy in Colon Cancer

Ana Maria Gonzalez-Angulo and Jyotsna Fuloria
Ochsner Journal June 2002, 4 (3) 163-167;

References

  1. ↵
    1. Lechner P.,
    2. Lind P.,
    3. Goldenberg D. M.
    (2000) Can postoperative surveillance with serial CEA immunoscintigraphy detect resectable rectal cancer recurrence and potentially improve tumor-free survival? J Am Coll Surg 191:511–518, pmid:11085731.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Cohen M. C.,
    2. Minsky B. D.,
    3. Schilsky R. L.
    (2001) Cancer of the colon. Cancer Principals and Practice of Oncology, 1216–1218, IN: DeVita VT, Hellman S, Rosenberg, SA, eds, 6th Edition. Philadelphia, PA: Lippincott.
  3. ↵
    1. Popescu R. A.,
    2. Norman A.,
    3. Ross P. J.
    (1999) Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17:2412–2418, pmid:10561304.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Petrelli N.,
    2. Douglass H. O. Jr.,
    3. Herrera L.
    (1989) The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 7:1419l–1426, pmid:2674331.
    OpenUrlPubMed
  5. ↵
    1. Erlichman C.,
    2. Fine S.,
    3. Wong A.
    (1988) A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469–475, pmid:3280741.
    OpenUrlAbstract
  6. ↵
    1. Lokich J. J.,
    2. Ahlgren J. D.,
    3. Gullo J. J.
    (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 7:425–432, pmid:2926468.
    OpenUrlAbstract
  7. ↵
    (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 16:301–308, pmid:9440757.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Hoff P. M.,
    2. Pazdur R.
    (1998) UFT plus oral leucovorin: a new oral treatment for colorectal cancer. Oncologist 3:155–164, pmid:10388099.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Miwa M.,
    2. Ura M.,
    3. Nishida M.
    (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-flouroracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281, pmid:9849491.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Twelves C.,
    2. Harper P.,
    3. van Custern E.
    (1999) A phase III trial (S014796) of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 18:1010A.
    OpenUrl
  11. ↵
    1. Hoff P. M.,
    2. Ansari R.,
    3. Batist G.
    (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282–2292, pmid:11304782.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Pazdur R.,
    2. Douillard J-Y.,
    3. Skillings J.
    (1999) Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 18:1009A.
    OpenUrl
  13. ↵
    1. Saltz L. B.,
    2. Cox J. V.,
    3. Blanke C.
    (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914, pmid:11006366.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Douillard J. Y.,
    2. Cunningham D.,
    3. Roth A. D.
    (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047, pmid:10744089.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Rothenberg M. L.,
    2. Meropol N. J.,
    3. Poplin E. A.
    (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19:3801–3807, pmid:11559717.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Giacchetti S.,
    2. Perpoint B.,
    3. Zidani R.
    (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136–147, pmid:10623704.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Harmantas A.,
    2. Rotstein L. E.,
    3. Langer B.
    (1996) Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer 78:1639–1645, pmid:8859174.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    (1996) Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst 88:252–258, pmid:8614003.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Kemeny N.,
    2. Huang Y.,
    3. Cohen A. M.
    (1999) Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341:2039–2048, pmid:10615075.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Kemeny M. M.,
    2. Adack S.,
    3. Gray B.
    (2002) Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy- an intergroup study. J Clin Oncol 20:1499–1505, pmid:11896097.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Pazdur R.,
    2. Vincent M.
    (1997) Raltitrexed (Tomudex) versus 5-fluoruracil and leucovorin (5-FU+LV) in patients with advanced colorectal cancer (ACC). Results of a randomized multicenter North American trial. Proc Am Soc Clin Oncol 16:201A.
    OpenUrl
  22. ↵
    1. Wolmark N.,
    2. Bryant J.,
    3. Smith R.
    (1998) Adjuvant 5-fluorouracil and leucovorin with or without interferon alpha-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 90:1810–1816, pmid:9839521.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Wolmark N.,
    2. Fisher B.,
    3. Rockette H.
    (1988) Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 80:30–36, pmid:3276901.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Laurie J. A.,
    2. Moertel C. G.,
    3. Fleming T. R.
    (1989) Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7:1447–1456, pmid:2778478.
    OpenUrlAbstract
  25. ↵
    1. Moertel C. G.,
    2. Fleming T. R.,
    3. Macdonald J. S.
    (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352–358, pmid:2300087.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Moertel C. G.,
    2. Fleming T. R.,
    3. Macdonald J. S.
    (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321–326, pmid:7847642.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. O'Connell M. J.,
    2. Laurie J. A.,
    3. Kahn M.
    (1998) Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295–300, pmid:9440756.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Buroker T. R.,
    2. O'Connell M. J.,
    3. Wieand H. S.
    (1994) Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14–20, pmid:7677801.
    OpenUrlAbstract
  29. ↵
    1. Haller D. G.,
    2. Catalano P. J.,
    3. MacDonald J. S.
    (1998) Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: Five year final report of INT-0089. Proc Am Soc Clin Oncol 17:A982.
    OpenUrl
  30. ↵
    1. Jager E.,
    2. Heike M.,
    3. Bernhard H.
    (1996) Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 14:2274–2279, pmid:8708717.
    OpenUrlAbstract
  31. ↵
    1. Sargent D. J.,
    2. Goldberg R. M.,
    3. Jacobson S. D.
    (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091–1097, pmid:11596588.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    1. Moertel C. G.,
    2. Fleming T. R.,
    3. Macdonald J. S.
    (1995) Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 13:2936–2943, pmid:8523058.
    OpenUrlAbstract
  33. ↵
    1. Mamounas E.,
    2. Wieand S.,
    3. Wolmark N.
    (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17:1349–1355, pmid:10334518.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Caner Trials (IMPACT B2) Investigators. J Clin Oncol 17:1356–1363, pmid:10334519.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Merkel S.,
    2. Wein A.,
    3. Günther K.
    (2001) High-risk groups of patients with Stage II colon carcinoma. Cancer 92:1435–1443, pmid:11745220.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Saltz L.,
    2. Rubin M.,
    3. Hochster H.
    (2001) Cetuximab (IMC- C225) plus irinotecan (CPT-11) is active in CPT-11refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20:3a, (abstr 7).
    OpenUrl
  37. ↵
    1. Riethmuller G.,
    2. Schneider-Gadicke E.,
    3. Schlimok G.
    (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343:1177–1183, pmid:7909866.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Riethmuller G.,
    2. Holz E.,
    3. Schlimok G.
    (1998) Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 16:1788–1794, pmid:9586892.
    OpenUrlAbstract
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section